Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Shares Outstanding (Weighted Average) (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $49.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.83% to $49.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.7 million through Dec 2025, up 3.83% year-over-year, with the annual reading at $49.7 million for FY2025, 3.83% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $49.7 million in Q4 2025 for Axsome Therapeutics, down from $50.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $50.0 million in Q3 2025 to a low of $50796.0 in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $42.8 million across 4 years, with a median of $46.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 89326.75% in 2023 and later grew 3.12% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $50796.0 in 2022, then skyrocketed by 89326.75% to $45.4 million in 2023, then grew by 5.48% to $47.9 million in 2024, then rose by 3.83% to $49.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AXSM at $49.7 million in Q4 2025, $50.0 million in Q3 2025, and $49.2 million in Q2 2025.